Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Interleukin-16 is increased in obesity and alters adipogenesis and inflammation in vitro

  • Reyes-Farias, Marjorie|||0000-0001-9179-7251
  • Fernández-García, Pablo|||0000-0001-8018-5954
  • Corrales, Patricia|||0000-0002-9817-8389
  • González, Lorena
  • Soria-Gondek, Andrea|||0000-0002-7210-0073
  • Martínez, Ester
  • Pellitero, Silvia|||0000-0002-9510-7251
  • Tarascó, Jordi
  • Moreno Santabarbara, Pablo|||0000-0002-6652-120X
  • Sumoy, Lauro|||0000-0003-0005-4618
  • Medina-Gómez, Gema|||0000-0001-8169-681X
  • Sánchez-Infantes, David|||0000-0001-6086-7501
  • Herrero, Laura|||0000-0003-4244-4673
Introduction: Obesity is a chronic condition associated with low-grade inflammation mainly due to immune cell infiltration of white adipose tissue (WAT). WAT is distributed into two main depots: subcutaneous WAT (sWAT) and visceral WAT (vWAT), each with different biochemical features and metabolic roles. Proinflammatory cytokines including interleukin (IL)-16 are secreted by both adipocytes and infiltrated immune cells to upregulate inflammation. IL-16 has been widely studied in the peripheral proinflammatory immune response; however, little is known about its role in adipocytes in the context of obesity. Aim & Methods: We aimed to study the levels of IL-16 in WAT derived from sWAT and vWAT depots of humans with obesity and the role of this cytokine in palmitate-exposed 3T3-L1 adipocytes. Results: The results demonstrated that IL-16 expression was higher in vWAT compared with sWAT in individuals with obesity. In addition, IL-16 serum levels were higher in patients with obesity compared with normal-weight individuals, increased at 6 months after bariatric surgery, and at 12 months after surgery decreased to levels similar to before the intervention. Our in vitro models showed that IL-16 could modulate markers of adipogenesis (Pref1), lipid metabolism (Plin1, Cd36, and Glut4), fibrosis (Hif1a, Col4a, Col6a, and Vegf), and inflammatory signaling (IL6) during adipogenesis and in mature adipocytes. In addition, lipid accumulation and glycerol release assays suggested lipolysis alteration. Discussion: Our results suggest a potential role of IL-16 in adipogenesis, lipid and glucose homeostasis, fibrosis, and inflammation in an obesity context.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

  • Weber, Minéia
  • Mera, Paula|||0000-0001-8941-4637
  • Casas, Josefina|||0000-0002-7926-5209
  • Salvador, Javier
  • Rodríguez, Amaia|||0000-0002-2180-461X
  • Alonso Muñoz, Sergio|||0000-0002-3989-8757
  • Sebastián, David|||0000-0002-7260-3869
  • Soler Vázquez, M. Carmen|||0000-0003-1430-5617
  • Montironi, Carla|||0000-0002-1453-2193
  • Recalde, Sandra|||0000-0002-6174-0649
  • Fucho, Raquel|||0000-0002-1774-9099
  • Calderon-Dominguez, María|||0000-0003-1797-3450
  • Mir, Joan Francesc|||0000-0001-8501-0969
  • Bartrons, Ramon|||0000-0001-9349-5847
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sánchez-Infantes, David|||0000-0001-6086-7501
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Casals, Nuria|||0000-0002-6719-4300
  • Valentí, Victor|||0000-0002-7074-2849
  • Frühbeck, Gema|||0000-0002-8305-7154
  • Herrero, Laura|||0000-0003-4244-4673
  • Serra, Dolors|||0000-0002-4936-4206
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high-fat diet (HFD)-induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno-associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD-induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9-hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD-induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans.